COMMUNIQUÉS West-GlobeNewswire

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01/06/2024
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were presented at ASCO 2024 [...]
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
01/06/2024
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and potent upregulation of [...]
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
01/06/2024
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior [...]
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT®▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
31/05/2024
Submission is supported by data from the Phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting 1 New formulation showed non-inferiority to intravenous administration in [...]
RYBREVANT®▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
31/05/2024
Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease 1 Landmark Phase 3 MARIPOSA data featured in an [...]
Mainz Biomed Reports Results of 2024 Annual General Meeting
31/05/2024
BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, held its annual general [...]
Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
31/05/2024
HOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported [...]
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
31/05/2024
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative [...]
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to July 3, 2024
31/05/2024
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced that today, its sponsor, Vision Sensing, LLC, [...]
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31/05/2024
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy brenetafusp (IMC-F106C) in [...]
Fortrea lance une solution complète pour améliorer la diversité et l’inclusion dans la recherche clinique
31/05/2024
Exploitation des données en conditions réelles, des connaissances des patients et adoption d’un processus systématique pour développer, concrétiser et mesurer l’efficacité des plans d’action en faveur de la diversité [...]
EAACI Congress Kicks Off in Valencia, Spain
31/05/2024
Precision Medicine, Immunotherapy, and Artificial Intelligence (AI) as Key Topics VALENCIA, Spain, May 31, 2024 (GLOBE NEWSWIRE) -- The EAACI International Congress has commenced with the slogan “Revolutionizing patient [...]
Smart for Life to be Featured in Whole Foods Magazine Highlighting Product Offerings, Strategic Acquisitions and Expansion Initiatives
31/05/2024
Company Representatives to Explore Strategies for Emerging Growth Companies in the Health & Wellness Sector MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL), a prominent leader in the [...]
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
31/05/2024
Local startup Oncobiotix to receive $100,000 to advance cancer and microbiome research CALGARY, Alberta, May 31, 2024 (GLOBE NEWSWIRE) -- The Alberta Cancer Foundation is pleased to announce the latest recipient of the [...]
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
31/05/2024
If approved, IXCHIQ ® will become the first vaccine available in the EU against the chikungunya virus (CHIKV) Decision on EU marketing authorization expected in the third quarter of 2024 Saint Herblain (France), May 31 [...]
Valneva reçoit un avis positif du CHMP pour une autorisation de mise sur le marché en Europe de son vaccin contre le chikungunya
31/05/2024
En cas d’approbation, IXCHIQ ® deviendra le premier vaccin disponible dans l'UE contre le virus du chikungunya (CHIKV) Une décision sur la demande d’autorisation de mise sur le marché européen est attendue au troisième [...]
OPKO Health to Participate in the Jefferies Global Healthcare Conference
31/05/2024
MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott [...]
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
31/05/2024
COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval [...]
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
31/05/2024
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, [...]

Pages